Kelzy

Dienogest/Ethinylestradiol, the active ingredient in Kelzy, is a combined oral contraceptive presented as an oral tablet for oral use. It is indicated for preventing pregnancy and for regulating menstrual cycles in women of reproductive age. It provides a reliable option for women seeking effective hormonal contraception.

GNH USA supplies Kelzy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics. The product meets European Union marketing authorisation standards and is distributed through GNH USA's established supply chain network.

Kelzy, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent ovulation and manage menstrual disorders.

- Prevention of pregnancy: provides reliable contraception by inhibiting ovulation. - Regulation of menstrual cycles: helps achieve more predictable bleeding patterns. - Management of menstrual‑related symptoms: reduces dysmenorrhea and heavy menstrual bleeding. - Control of androgenic symptoms: may improve acne and reduce excess hair growth.

Kelzy may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Headache - Breast tenderness - Spotting or irregular bleeding

Serious or Rare Side Effects: - Deep‑vein thrombosis or pulmonary embolism - Stroke or myocardial infarction - Severe hypertension or liver tumor

Before prescribing Kelzy, clinicians should consider several safety factors.

- Contraindicated in pregnancy: product is classified Category X and must not be used. - Avoid in women with a history of thromboembolic disorders: increased risk of clot formation. - Screen for hypertension: monitor blood pressure regularly during therapy. - Do not use with estrogen‑sensitive cancers: may stimulate tumor growth. - Smoking in women over 35 years: markedly raises cardiovascular risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Kelzy can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may reduce hormonal levels and contraceptive efficacy. - Anticoagulants (e.g., warfarin) may increase bleeding risk when combined with the estrogen component.

Moderate Interactions (Monitor Closely): - Certain antiepileptics (e.g., carbamazepine) can lower hormone concentrations. - Selective serotonin reuptake inhibitors (e.g., fluoxetine) may heighten mood‑related side effects. - Grapefruit juice may increase plasma levels of ethinylestradiol, raising the risk of adverse events.